FDA: Hospira recalls one lot of 0.25% Bupivacaine Hydrochloride Injection

Editor's Note

The Food and Drug Administration (FDA) on August 5 reported that Hospira, Inc (Lake Forest, Illinois) is recalling one lot of 0.25% Bupivacaine Hydrochloride Injection, USP (NDC: 0409-1159-02, Lot 59-064-DK, Expiry 1 Nov 2017) because of the presence of particulate matter found in a single vial.

The lot was distributed nationwide between December 2015 and January 2016.

Posted 08/05/2016] AUDIENCE: Pharmacy, Risk Manager, OBGYN, Dentistry ISSUE: Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of 0.25% Bupivacaine Hydrochloride Injection, USP (NDC: 0409-1159-02, Lot 59-064- DK, Expiry 1NOV2017) at the hospital/retail level due to the presence of particulate matter within a single vial.